Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: A systematic review and meta-analysis

Obstetrics and Gynecology

Volumn 115, Issue 6, 2010, Pages 1256-1262

  Ziakas, Panayiotis D ^a   Pavlou, Matthaios ^a   Voulgarelis, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; BIRTH RATE; BLEEDING; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPISTAXIS; FIRST TRIMESTER PREGNANCY; HUMAN; LIVE BIRTH; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MONOTHERAPY; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RECURRENT ABORTION; REVIEW; SKIN BRUISING; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; PREGNANCY;

EID: 77952981639     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181deba40     Document Type: Review

References (42)

1. Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy-a systematic review of randomized therapeutic trials. Thromb Res 2004;114:419-426
2. Tincani A, Branch W, Levy RA, Piette JC, Carp H, Rai RS, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003;12:524-529
3. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301-3304
4. Takakuwa K, Asano K, Arakawa M, Yasuda M, Hasegawa I, Tanaka K. Chromosome analysis of aborted conceptuses of recurrent aborters positive for anticardiolipin antibody. Fertil Steril 1997;68:54-58
5. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism. N Engl J Med 1997;337:154-160
6. Woodhams BJ, Candotti G, Shaw R, Kernoff PB. Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb Res 1989;55:99-107.
7. Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to beta2-glycopro-tein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998;352:1037-1038
8. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-257
9. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-1589
10. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001;357:1027-1032
11. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J; American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 suppl): 844S-86S.
12. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-413
13. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009;36:279-287
14. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005;(2): CD002859.
15. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboem-bolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401-407
16. Canales JF, Ferguson JJ. Low-molecular-weight heparins: mechanisms, trials, and role in contemporary interventional medicine. Am J Cardiovasc Drugs 2008;8:15-25.
17. Camporese G, Bernardi E. Low-molecular-weight heparin for thromboprophylaxis. Curr Opin Pulm Med 2009;15:443-454
18. Happe LE, Farrelly EM, Stanford RH, Sarnes MW. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries. J Thromb Thrombolysis 2008;26:125-131
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
21. Greenland S, Robins J. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55-68.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
23. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005;83:684-690
24. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated hepa-rin. J Obstet Gynaecol Can 2004;26:729-734
25. Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod 2002;17:2981-2985
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634
27. Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticar-diolipin antibodies. Med Sci Monit 2006;12:CR132-6.
28. Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010;49:281-288
29. Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996;35:402-407
30. Bose P, Black S, Kadyrov M, Bartz C, Shlebak A, Regan L, et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 2004;191:2125-2131
31. Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, et al. Arterial thrombosis, intrauterine death and "lupus" antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981;1:244-246
32. Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 2005;192:23-30.
33. Di Simone N, Luigi MP, Marco D, Fiorella DN, Silvia D, Clara DM, et al. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Ann N Y Acad Sci 2007;1108:505-514
34. Magid MS, Kaplan C, Sammaritano LR, Peterson M, Druzin ML, Lockshin MD. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol 1998;179:226-234
35. Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 2003;12:535-538
36. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphos-pholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004;10:1222-1226
37. D'Ippolito S, Di Simone N, Di Nicuolo F, Castellani R, Caruso A. Antiphospholipid antibodies: effects on trophoblast and endothelial cells. Am J Reprod Immunol 2007;58:150-158 (Pubitemid 47097381)
38. Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod 1997;56:50-58
39. Di Simone N, Raschi E, Testoni C, Castellani R, D'Asta M, Shi T, et al. Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. Ann Rheum Dis 2005;64:462-467
40. Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod 2002;17:1067-1071
41. Ermel LD, Marshburn PB, Kutteh WH. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL). Am J Reprod Immunol 1995;33:14-20.
42. Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 2003;101:455-462